NMTC director granted options and RSUs
NEUROONE MEDICAL TECHNOLOGIES Corp director Jeffrey S. Mathiesen received new equity compensation.
Rhea-AI Filing Summary
NEUROONE MEDICAL TECHNOLOGIES Corp director Jeffrey S. Mathiesen received new equity compensation. On April 3, 2026, he was granted options to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036. These options vest in 12 equal monthly installments over one year.
On the same date, he also received 41,929 restricted stock units, which vest in 12 equal monthly installments over one year at the end of each month. Following these grants, he directly owns 156,343 shares of common stock. Both grants are compensation awards rather than open-market purchases.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to Purchase Common Stock | 26,036 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 41,929 | $0.00 | $0.00 |
Footnotes (2)
- F1. Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.
- F2. The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.
Key Figures
Key Terms
restricted stock units financial
vesting financial
exercise price financial
expiration date financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did NMTC director Jeffrey Mathiesen receive in this Form 4?
How do the new restricted stock units for NMTC vest for Jeffrey Mathiesen?
What are the key terms of Jeffrey Mathiesen’s NMTC stock options?
Are the NMTC transactions in this Form 4 open-market buys or compensation grants?
What is the significance of the vesting schedule for NMTC’s director equity awards?
AI-generated analysis. How Rhea-AI works. Not financial advice.